Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 63, Issue 10-11, Pages 943-955Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2011.05.021
Keywords
Adjuvant; Cancer; Vaccine; PLGA
Categories
Funding
- Canadian Health Institute of Research [MOP 42407]
- Natural Sciences and Engineering Council of Canada [STPGP 336987]
Ask authors/readers for more resources
Development of safe and effective cancer vaccine formulation is a primary focus in the field of cancer immunotherapy. The recognition of the crucial role of dendritic cells (DCs) in initiating anti-tumor immunity has led to the development of several strategies that target vaccine antigens to DCs as an attempt for developing potent, specific and lasting anti-tumor T cell responses. The main objective of this review is to provide an overview on the application of poly (D,L-lactic-co-glycolic acid) nanoparticles (PLGA-NPs) as cancer vaccine delivery system and highlight their potential in the development of future therapeutic cancer vaccines. PLGA-NPs containing antigens along with immunostimulatory molecules (adjuvants) can not only target antigen actively to DCs, but also provide immune activation and rescue impaired DCs from tumor-induced immuosupression. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available